Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody–drug conjugate therapeutic

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med.346(7),469–475 (2002).
  Medline CASGoogle Scholar
• 2  Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnology24(6),274–280 (2006).
  Medline CASGoogle Scholar
• 3  Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunological Methods289(1–2),1–16 (2004).▪ White Paper providing recommendations for the development of immunoassays to detect anti-therapeutic antibodies during preclinical and clinical studies.
  Medline CASGoogle Scholar
• 4  Wadhwa M, Thorpe R. Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis2(6),1073–1084 (2010).
  CASGoogle Scholar
• 5  Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods304(1–2),189–195 (2005).
  Medline CASGoogle Scholar
• 6  Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol.20(4),493–499 (2008).
  Medline CASGoogle Scholar
• 7  Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods365(1–2),38–49 (2011).▪ Evaluates several immunoassay platforms for detection of anti-therapeutic antibodies and discusses the development of a solution ELISA with optimal drug tolerance and robust assay performance. In this assay, a monoclonal antibody that competed with the therapeutic for binding its target was utilized to overcome interference by the multimeric soluble target.
  Medline CASGoogle Scholar
• 8  Maia M, Lowe J, Wakshull E, Quarmby V. A novel strategy for elimination of soluble-ligand interference in immunogenicity assays. Presented at: AAPS National Biotechnology Conference. Seattle, WA, USA 21–24 June 2009.
  Google Scholar
• 9  Zhong ZD, Dinnogen S, Hokom M et al. Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods355(1–2),21–28 (2010).▪ Presents a statistical approach to identify soluble target interference in a bridging electrochemiluminescence immunoassay and evaluate complex interactions between the therapeutic, the anti-therapeutic antibodies and the target in free and complexed forms. A monoclonal antibody that competed with the therapeutic for binding to the target was used to eliminate the soluble target interference.
  Medline CASGoogle Scholar
• 10  Chen Y, Clark S, Wong T et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res.67(10),4924–4932 (2007).
  Medline CASGoogle Scholar
• 11  Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol.26(8),925–932 (2008).
  Medline CASGoogle Scholar
• 12  O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biology: J. Intl Soc. Oncodevelopmental Biol. Med.22(6),348–366 (2001).
  MedlineGoogle Scholar
• 13  Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.276(29),27371–27375 (2001).
  Medline CASGoogle Scholar
• 14  Kui Wong N, Easton RL, Panico M et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem.278(31),28619–28634 (2003).
  MedlineGoogle Scholar
• 15  Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Investig.68(5),1331–1337 (1981).
  MedlineGoogle Scholar
• 16  Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int. J. Biological Markers13(4),179–187 (1998).
  Medline CASGoogle Scholar
• 17  Sturgeon CM, Duffy MJ, Stenman UH et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem.54(12),e11–79 (2008).
  Medline CASGoogle Scholar
• 18  Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal.48(5),1267–1281 (2008).▪ White Paper providing recommendations for best practices to test performance characteristics for the validation of anti-therapeutic antibody immunoassays.
  Medline CASGoogle Scholar
• 19  Warren DJ, Nustad K, Beard JB, O’Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: fourth report from the ISOBM TD-1 workshop. Tumour Biol.30(2),51–60 (2009).
  MedlineGoogle Scholar
• 20  Sharon N. Lectin-carbohydrate complexes of plants and animals: an atomic view. Trends Biochem. Sci.18(6),221–226 (1993).
  Medline CASGoogle Scholar
• 21  Gubbels JA, Belisle J, Onda M et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer5(1),50 (2006).
  MedlineGoogle Scholar
• 22  Hongsachart P, Huang-Liu R, Sinchaikul S et al. Glycoproteomic analysis of WGA-bound glycoprotein biomarkers in sera from patients with lung adenocarcinoma. Electrophoresis30(7),1206–1220 (2009).
  Medline CASGoogle Scholar
• 23  Venegas M, Liu L, Lovell L et al. Purification and immunochemical characterization of ascitic fluid glycoproteins containing certain tumor-associated and blood group antigen markers. Glycoconjugate J.6(4),511–524 (1989).
  Medline CASGoogle Scholar
• 24  Chrispeels MJ, Raikhel NV. Lectins, lectin genes, and their role in plant defense. Plant Cell3(1),1–9 (1991).
  Medline CASGoogle Scholar
• 25  Klein A, Michalski JC, Morelle W. Modifications of human total serum N-glycome during liver fibrosis-cirrhosis, is it all about immunoglobulins? Proteomics. Clin. Appl.4(4),372–378 (2010).
  Medline CASGoogle Scholar
• 26  Yamaguchi Y, Takahashi N, Kato K. Molecular interactions: Antibody structures. In: Comprehensive Glycoscience. Kamerling JP (Ed.). Elsevier Ltd, Oxford, UK, 745–763 (2007).
  Google Scholar
• 27  Burton DR. Structure and function of antibodies. In: Molecular Genetics of Immunoglobulin. Calabi F, Neuberger MS (Eds). Elsevier, Amsterdam, New York, Oxford, 1–50 (1987).
  Google Scholar
• 28  Suzuki N, Lee YC. Site-specific N-glycosylation of chicken serum IgG. Glycobiology14(3),275–292 (2004).
  Medline CASGoogle Scholar
• 29  Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann. Oncol.17(8),1234–1238 (2006).
  Medline CASGoogle Scholar
• 30  US FDA. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. US Department of Health and Human Services Food and Drug Administration (2009).▪▪ Draft guidance providing recommendations for the development of immunoassays to evaluate the immunogencity of therapeutic proteins during clinical development.
  Google Scholar
• 31  Garofolo F, Rocci ML Jr, Dumont I et al. 2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis3(18),2081–2096 (2011).
  CASGoogle Scholar
• 32  Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol.13(3),245–255 (2009).
  Medline CASGoogle Scholar
• 33  Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng. Des. Sel.24(1–2),3–9 (2011).
  Medline CASGoogle Scholar
• 34  Mairal T, Ozalp VC, Lozano Sanchez P, Mir M, Katakis I, O’Sullivan CK. Aptamers: molecular tools for analytical applications. Anal. Bioanal. Chem.390(4),989–1007 (2008).
  Medline CASGoogle Scholar